Engineered Cytokine‐Primed Extracellular Vesicles with High PD‐L1 Expression Ameliorate Type 1 Diabetes

Lanxing Wang; Chunxiao Qi; Hongmei Cao; Yanwen Zhang; Xing Liu; Lina Qiu; Hang Wang; Lijuan Xu; Zhenhua Wu; Jianfeng Liu; Shusen Wang; Deling Kong; Yuebing Wang

doi:10.1002/smll.202301019

May 20, 2023Small

Engineered Cytokine‐Primed Extracellular Vesicles with High PD‐L1 Expression Ameliorate Type 1 Diabetes

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate whether engineered, cytokine-primed extracellular vesicles expressing high levels of PD-L1 can modulate the immune microenvironment and treat type 1 diabetes.
Engineered cytokine-primed extracellular vesicles tailored with high PD-L1 surface expression.
Tested therapeutic efficacy and immune remodeling mechanisms in mouse models of type 1 diabetes.
Regulated T cell density and activation via the PD-L1/PD-1 pathway.
Promoted an M1-to-M2 macrophage phenotype transition to reshape the local immune microenvironment.
Achieved high therapeutic efficiency in diabetic mice, establishing utility for both disease imaging and immunotherapy.

Implication

Animal study demonstrates engineered extracellular vesicles ameliorate type 1 diabetes in mice, highlighting a novel therapeutic and imaging strategy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2023) studied this question.

synapsesocial.com/papers/6a0378748cb95a7d958a3258 https://doi.org/10.1002/smll.202301019

View Full Paper

Ask AI

Bookmark

Share

Engineered Cytokine‐Primed Extracellular Vesicles with High PD‐L1 Expression Ameliorate Type 1 Diabetes

Key Points

Implication

Discussion

Cite This Study

Engineered Cytokine‐Primed Extracellular Vesicles with High PD‐L1 Expression Ameliorate Type 1 Diabetes

Key Points

Implication

Discussion

Cite This Study

Keep reading

Keep reading